Why all blood donations should be tested for hepatitis E virus (HEV)

Hepatitis E virus (HEV) is a growing concern in industrialized countries due to its potential transmission through blood transfusion. While HEV-1 and HEV-2 are primarily linked to waterborne outbreaks in Asia, HEV-3 and HEV-4 are more prevalent in regions with moderate climates. HEV-3, in particular, has been detected in blood donations and poses a risk to vulnerable recipients. The rise in reported HEV cases highlights a need for updated screening protocols. Prior research has established HEV as a zoonotic threat, especially through undercooked pork consumption and pig contact. However, the risk of HEV-3 in blood transfusion systems remains underappreciated. This gap motivates a reevaluation of current blood donation practices. No prior work has resolved the extent of HEV-3 transmission via transfusion in immunocompromised individuals. The increasing prevalence of HEV-3 in blood donations underscores the urgency of this issue.

This article aims to evaluate the necessity of testing all blood donations for HEV-3. The specific problem is the potential risk of HEV-3 transmission through blood transfusion, particularly to immunocompromised patients or those with preexisting liver conditions. The motivation stems from the observed rise in HEV-3 infections and documented cases of transfusion-related transmission. The authors argue that current screening practices may not be sufficient to prevent HEV-related complications in high-risk recipients. The study focuses on HEV-3 due to its growing presence in industrialized nations. The goal is to determine whether universal HEV-3 screening is justified based on transmission risks and recipient vulnerability. This analysis is driven by the need to enhance blood transfusion safety. The authors propose that testing could reduce the likelihood of HEV-related liver failure in susceptible populations.

The authors conducted a review of existing literature on HEV-3 transmission through blood transfusion. They analyzed data on HEV-3 prevalence in blood donations and the clinical outcomes of transfusion-related infections. The study focused on HEV-3 due to its increasing incidence in industrialized countries. The approach involved synthesizing findings from published case reports and epidemiological studies. The authors examined the mechanisms of HEV-3 transmission, including asymptomatic carriage in donors. They evaluated the risk of HEV-3 infection in immunocompromised recipients and those with chronic liver disease. The analysis included comparisons of HEV genotypes and their transmission routes. The authors emphasized the importance of blood donor screening in reducing transfusion-related HEV transmission.

The study found that HEV-3 is increasingly detected in blood donations in industrialized countries. Transfusion-related HEV-3 infections have been documented, particularly in immunocompromised recipients. The risk of acute-on-chronic liver failure (ACLF) in these patients is significant. HEV-3 infections in healthy individuals are often asymptomatic, making detection challenging. The prevalence of HEV-3 in blood donations has risen in recent years. Transmission through blood transfusion can lead to severe liver complications. The authors report that HEV-3 has been linked to ACLF in patients with preexisting liver conditions. These findings support the argument for universal HEV-3 screening of blood donations.

The authors conclude that HEV-3 poses a transfusion-related risk to vulnerable populations. They argue that universal HEV-3 screening of blood donations is necessary to prevent transmission. The evidence suggests that HEV-3 can cause acute-on-chronic liver failure in immunocompromised recipients. The increasing prevalence of HEV-3 in blood donations supports the need for screening. The authors propose that testing could reduce the risk of HEV-related complications in high-risk patients. They emphasize that HEV-3 transmission through blood transfusion is a documented phenomenon. The study does not suggest that HEV-3 is the only transfusion-transmissible virus but highlights its growing significance. The authors state that current screening practices may not be sufficient to prevent HEV-3 transmission.